On 11 February 2023, the following updates were made to the Australian Immunisation Register (AIR).
The following new flu vaccines were added to the AIR:
- Afluria Quad (NIP) – AFLQUA
- Afluria Quad (Non-NIP) – QUADAF
- Fluarix Tetra (NIP) – FLXTET
- Fluarix Tetra (Non-NIP) – ARXFLU
The following flu vaccines are no longer registered or available for use in Australia, and therefore will no longer be available to be reported for use to the AIR:
- Afluria Quad - AFLR
- Fluva - FLUVAX
- Vaxigrip - VAXGRP
- Fluarix - FLRIX
- Fluarix Tetra - FLUTET
- FluQuadri Junior - FQDJN
- Fluvirin - FLVRN
- Panvax - PANVAX
- Influvac - INFLUV
- Agrippal - AGRPAL
- Vaxigrip Junior - VGRJNR
- Fluvax Junior - FVXJNR
- Fluad - FLUAD
- Fluzone High-Dose – FLUHID
Please note: vaccination providers will still be able to report these vaccines if they were administered prior to 11 February 2023. Flu vaccines reported prior to 11 February 2023 will remain recorded on the AIR and display on individuals’ vaccination evidence.
In instances where an individual has been vaccinated and the brand is not available (i.e., overseas), vaccination providers can report it as a generic vaccine brand (e.g., ‘Generic Influenza’).
Reporting flu vaccinations to the AIR
It is mandatory to report all flu vaccinations administered, whether they are funded under the National Immunisation Program or privately purchased, to the AIR.
When reporting to the AIR:
- select the relevant vaccine name (i.e. (NIP) for NIP funded vaccines and (Non-NIP) for privately purchased vaccines).
- only the vaccine brand name will display on a persons Immunisation History Statement (e.g., Afluria Quad (NIP) will display as “Afluria Quad”).
- providers will be able to report under these names using their clinical software. If a particular vaccine has been used and does not appear, contact your software provider. Alternatively, vaccines can be reported using the AIR site.